Scotiabank Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $41.00

Keros Therapeutics (NASDAQ:KROSFree Report) had its price target decreased by Scotiabank from $44.00 to $41.00 in a research report report published on Thursday,Benzinga reports. Scotiabank currently has a sector outperform rating on the stock.

Several other equities analysts have also recently issued reports on KROS. Wells Fargo & Company lifted their price objective on Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Truist Financial lowered their price objective on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, December 23rd. Guggenheim cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Keros Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $52.56.

Read Our Latest Research Report on Keros Therapeutics

Keros Therapeutics Stock Up 3.2 %

Shares of KROS opened at $10.86 on Thursday. Keros Therapeutics has a 52-week low of $9.77 and a 52-week high of $73.00. The company has a 50-day simple moving average of $36.37 and a 200-day simple moving average of $47.13. The company has a market capitalization of $439.94 million, a PE ratio of -2.08 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROSGet Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same quarter in the prior year, the firm earned ($1.33) EPS. The company’s revenue for the quarter was up 4750.0% compared to the same quarter last year. On average, research analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. increased its stake in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the last quarter. Alkeon Capital Management LLC grew its holdings in Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares during the period. Parkman Healthcare Partners LLC increased its stake in shares of Keros Therapeutics by 112.3% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock valued at $24,493,000 after acquiring an additional 223,155 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Keros Therapeutics by 814.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after acquiring an additional 199,245 shares during the period. Finally, FMR LLC boosted its position in shares of Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after acquiring an additional 179,374 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Featured Articles

Analyst Recommendations for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.